On March 7, 2023 iPSirius, a leading biotechnology company focused on the development of innovative immunotherapies, reported that it has been granted its second American patent for a novel technology that enables the production of ‘off-the-shelf’ cancer vaccines from induced pluripotent stem cells (iPSCs) (Press release, iPSirius, MAR 7, 2023, https://bioinformant.com/ipsirius-patent-ipvac-cancer-vaccine/ [SID1234641002]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The newly granted patent covers the proprietary methods developed by iPSirius for the production of their proprietary IPVAC off-the-shelf cancer vaccines. The first patent granted to the company in the USA currently allows the preparation of a pre-IND and the Company sees the extension of its American patent portfolio as significant to its efforts to scale its clinical and manufacturing programs over the coming years.
"We are thrilled to have been granted our second American patent for this groundbreaking technology," said Prof. Frank Griscelli, co-founder of iPSirius. "This is a major milestone for our company and further validates the potential of iPSC-based cancer vaccines to transform the treatment of a wide range of cancers. Our proprietary IPVAC technology is a key part of our pipeline of innovative cancer vaccines, and we are excited to continue developing and optimizing this technology to advance the field of cancer immunotherapy."
iPSirius has a strong pipeline of innovative off-the-shelf cancer vaccines in development, based on their proprietary IPVAC technology. With this new patent, the company has strengthened its position as a leader in the rapidly growing fields of cancer immunotherapy and iPSC therapeutics.